Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature

Katie Pricola Fehnel, Micah Duggins-Warf, David Zurakowski, Maxwell McKee-Proctor, Rajarshi Majumder, Michael Raber, Xuezhe Han, Edward R. Smith

Research output: Contribution to journalArticle

Abstract

Objective The authors report the use of urinary biomarkers as a novel, noninvasive technique to detect juvenile pilocytic astrocytomas (JPAs), capable of distinguishing JPAs from other CNS diseases, including other brain tumors. Preliminary screening of an array of tumors implicated proteases (including matrix metalloproteinases [MMPs]) and their inhibitors (tissue inhibitors of metalloproteinase [TIMPs]) as well as growth factors (including basic fibroblast growth factor [bFGF]) as candidate biomarkers. These data led the authors to hypothesize that tissue inhibitor of metalloproteinase 3 (TIMP3) and bFGF would represent high-probability candidates as JPA-specific biomarkers. Methods Urine was collected from 107 patients, which included children with JPA (n = 21), medulloblastoma (n = 17), glioblastoma (n = 9), arteriovenous malformations (n = 25), moyamoya (n = 14), and age-and sex-matched controls (n = 21). Biomarker levels were quantified with enzyme-linked immunosorbent assay, tumor tissue expression was confirmed with immunohistochemical analysis, and longitudinal biomarker expression was correlated with imaging. Results were subjected to univariate and multivariate statistical analyses. Results Using optimal urinary cutoff values of bFGF > 1.0 pg/g and TIMP3 > 3.5 pg/g, multiplexing bFGF and TIMP3 predicts JPA presence with 98% accuracy. Multiplexing bFGF and MMP13 distinguishes JPA from other brain tumor subtypes with up to 98% accuracy. Urinary biomarker expression correlated with both tumor immunohistochemistry and in vitro tumor levels. Urinary bFGF and TIMP3 decrease following successful tumor treatment and correlate with changes in tumor size. Conclusions This study identifies 2 urinary biomarkers-bFGF and TIMP3-that successfully detect one of the most common pediatric brain tumors with high accuracy. These data highlight potential benefits of urinary biomarkers and support their utility as diagnostic tools in the treatment of children with JPA.

Original languageEnglish (US)
Pages (from-to)396-407
Number of pages12
JournalJournal of Neurosurgery: Pediatrics
Volume18
Issue number4
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Keywords

  • Basic fibroblast growth factor
  • BFGF
  • Oncology
  • Pilocytic astrocytoma
  • TIMP3
  • Tissue inhibitor of metalloproteinase 3
  • Urinary biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature'. Together they form a unique fingerprint.

  • Cite this

    Fehnel, K. P., Duggins-Warf, M., Zurakowski, D., McKee-Proctor, M., Majumder, R., Raber, M., Han, X., & Smith, E. R. (2016). Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature. Journal of Neurosurgery: Pediatrics, 18(4), 396-407. https://doi.org/10.3171/2015.12.PEDS15448